Skip to main content

Anika Therapeutics Value Stock - Dividend - Research Selection

Anika therapeutics

ISIN: US0352551081 , WKN: 889120

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!

How our site works ...

✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month 
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company\'s dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product used for the prevention of post-surgical spinal adhesions; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. has a strategic collaboration with the Institute for Applied Life Sciences at the University of Massachusetts Amherst to develop a therapy for rheumatoid arthritis. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study

2026-09-25
MRK's remigromig meets the primary goal in a DME study, showing non-inferiority to ranibizumab while further safety analyses continue.

Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?

2026-09-25
Here is how Anika Therapeutics (ANIK) and Concentra Group (CON) have performed compared to their sector so far this year.

AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study

2026-09-23
Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.

NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication

2026-09-21
NVS' Cosentyx wins a positive EU opinion for PMR, backed by late-stage data, potentially expanding its use beyond existing inflammatory conditions.

PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins

2026-09-18
Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.

B. Riley Securities Assumes Anika Therapeutics at Buy, Raises Price Target to $23

2026-09-18
B. Riley Securities analyst Madison El-Saadi assumes Anika Therapeutics (NASDAQ:ANIK) with a Buy rating and raises Price Target to $23.

RCKT Aligns With FDA on Completing Phase II Study in Danon Disease

2026-09-16
Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.

Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study

2026-09-15
IMCR achieves target enrollment in the phase III TEBE-AM study investigating Kimmtrak in previously treated patients with advanced melanoma.

Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder

2026-09-10
RHHBY's sBLA for Enspryng wins FDA priority tag for myelin oligodendrocyte glycoprotein antibody-associated disease. A decision is due on Jan. 10, 2027.

Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall

2026-09-09
NVS' del-desiran fails the HARBOR study's primary endpoint, adding to recent pipeline setbacks as investors await next steps.